A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
ConditionBiliary Tract Cancer (BTC)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedSIR
About this trial
The REVEAL-BTC Study will analyze 5 biomarkes in samples of participants who in the past 15 year have been diagnosed with any stage of biliary tract cancer. The expression levels of the biomarkers will be correlated with clinical outcomes in the participants, which will lead to better patient stratification that will help guide the use of targeted therapies in the future.
Eligibility criteria
Qualifiers
Written informed consent for the use of clinical data and tissue samples is available. (The use of data and samples without consent is only possible if exemption is granted by the corresponding Institutional Review Board - IRB).
Histologically confirmed diagnosis of biliary tract cancer (including gallbladder carcinoma [GBC] or cholangiocarcinoma [CCA]), regardless of disease stage.
Diagnosis must have been established within the last 15 years prior to Study initiation.
Availability of archival formalin-fixed paraffin-embedded (FFPE) tumor tissue sample, collected prior to Study inclusion at any disease stage (e.g., during surgery or in the advanced setting). For patients with de novo metastatic disease or early stage primary tumors undergoing surgery, the tissue must have been obtained before the initiation of any systemic therapy (e.g. chemotherapy) or radiotherapy. For patients with recurrent disease undergoing a new biopsy, previous treatments are allowed.
Disqualifiers
Unavailability or inadequate quality (e.g., insufficient tumor content, degraded tissue) of archival FFPE tumor tissue samples for the planned immunohistochemical analysis.
Missing or incomplete basic clinical and/or survival data in the medical record.
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
244 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
MedSIR
Lead sponsor
AstraZeneca
Collaborator
Source ClinicalTrials.gov